Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737

Lieber,Justus; Dewerth,Alexander; Wenz,Julia; Kirchner,Bettina; Eicher,Carmen; Warmann,Steven  W.; Fuchs,Jörg; Armeanu-Ebinger,Sorin

doi:10.3892/or.2012.2150

Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737

Authors:
- Justus Lieber
- Alexander Dewerth
- Julia Wenz
- Bettina Kirchner
- Carmen Eicher
- Steven W. Warmann
- Jörg Fuchs
- Sorin Armeanu-Ebinger
View Affiliations

Affiliations: Department of Paediatric Surgery and Paediatric Urology, University Children's Hospital, 72076 Tübingen, Germany
Published online on: November 27, 2012 https://doi.org/10.3892/or.2012.2150
Pages: 646-652

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The response of standard-risk hepatoblastoma (HB) to neoadjuvant cisplatin (CDDP) chemotherapy is excellent; however, in high-risk HB, drug resistance remains a major challenge. Alternative therapeutic strategies may consider combining cytotoxic drugs with apoptosis sensitizers as this has shown additive effects in various types of malignancies. Analysis of published expression databases have revealed an anti-apoptosis state in HB samples. Herein, we evaluated the synergistic effects of ABT-737 as a modulator of apoptosis in combination with CDDP in HB. To this end, clonogenic assays were performed with HepT1 and HUH6 HB cells to evaluate the synergistic effects of CDDP and ABT-737. Combination treatment with CDDP and ABT-737 reduced the clonogenicity of HB cells more than 5-fold compared to treatment with CDDP alone. Furthermore, the HUH6 mixed-type HB cells showed higher sensitivity to CDDP and combination treatment compared to the HepT1 embryonal-type cells. Subcutaneous HUH6 tumors in NOD/LtSz-scid IL2Rγnull mice were treated with CDDP (1.25 and 3 mg/kg body weight, n=6), ABT-737 (100 mg/kg, n=5) and the combination of both agents (n=5). Combined treatment led to a significantly reduced tumor growth compared to CDDP treatment alone (p<0.02). When using higher doses of CDDP (3 mg/kg) alone or in combination with ABT-737, dose-dependent toxicity was observed in this mouse strain. In conclusion, our results demonstrated the enhancement of chemotherapy efficacy by using modulators of apoptosis together with cytotoxic agents. Additive effects of ABT-737 may allow reduction in CDDP dosages with maintenance of antitumor activity. Sensitizing HB to apoptosis may also render resistant HB susceptible to established chemotherapy regimens.

View Figures

View References

1	Loehrer PJ and Einhorn LH: Drugs five years later. Cisplatin Ann Intern Med. 100:704–713. 1984.PubMed/NCBI
2	Perilongo G, Maibach R, Shafford E, et al: Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 361:1662–1670. 2009. View Article : Google Scholar : PubMed/NCBI
3	Pritchard J, Brown J, Shafford E, et al: Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach - results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 18:3819–3828. 2000.
4	Sullivan MJ: Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears. Cancer. 115:5623–5626. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ortega JA, Douglass EC, Feusner JH, et al: Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 18:2665–2675. 2000.PubMed/NCBI
6	Perilongo G, Shafford E, Maibach R, et al: Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology - SIOPEL 2. Eur J Cancer. 40:411–421. 2004. View Article : Google Scholar : PubMed/NCBI
7	Zsiros J, Maibach R, Shafford E, et al: Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol. 28:2584–2590. 2009. View Article : Google Scholar : PubMed/NCBI
8	Cvitkovic E: Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev. 24:265–281. 1998. View Article : Google Scholar : PubMed/NCBI
9	Knight KR, Kraemer DF and Neuwelt EA: Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 23:8588–8596. 2005. View Article : Google Scholar
10	Chonghaile TN and Letai A: Mimicking the BH3 domain to kill cancer cells. Oncogene. 27(Suppl 1): 149–157. 2008. View Article : Google Scholar : PubMed/NCBI
11	Lieber J, Kirchner B, Eicher C, et al: Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatr Blood Cancer. 55:1089–1095. 2010. View Article : Google Scholar : PubMed/NCBI
12	Adesina AM, Lopez-Terrada D, Wong KK, et al: Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol. 40:843–853. 2009. View Article : Google Scholar
13	Konopleva M, Contractor R, Tsao T, et al: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388. 2006. View Article : Google Scholar : PubMed/NCBI
14	Lieber J, Eicher C, Wenz J, et al: The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. BMC Cancer. 11:3622011. View Article : Google Scholar : PubMed/NCBI
15	Lieber J, Ellerkamp V, Wenz J, et al: Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells. Pediatr Surg Int. 28:149–159. 2012. View Article : Google Scholar : PubMed/NCBI
16	Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
17	Trudel S, Stewart AK, Li Z, et al: The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res. 13:621–629. 2007. View Article : Google Scholar : PubMed/NCBI
18	van Delft MF, Wei AH, Mason KD, et al: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 10:389–399. 2006.PubMed/NCBI
19	High LM, Szymanska B, Wilczynska-Kalak U, et al: The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 77:483–494. 2010. View Article : Google Scholar : PubMed/NCBI
20	Mason KD, Khaw SL, Rayeroux KC, et al: The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia. 23:2034–2041. 2009. View Article : Google Scholar : PubMed/NCBI
21	Cairo S, Armengol C, De Reynies A, et al: Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 14:471–484. 2008. View Article : Google Scholar : PubMed/NCBI
22	Doi I: Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann. 67:1–10. 1976.PubMed/NCBI
23	Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK and von Schweinitz D: Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest. 74:809–818. 1996.PubMed/NCBI
24	Warmann SW, Heitmann H, Teichmann B, et al: Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma. Pediatr Hematol Oncol. 22:373–386. 2005. View Article : Google Scholar : PubMed/NCBI
25	Reynolds M: Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study. World J Surg. 19:814–816. 1995. View Article : Google Scholar : PubMed/NCBI
26	Haberle B, Bode U and von Schweinitz D: Differentiated treatment protocols for high- and standard-risk hepatoblastoma - an interim report of the German Liver Tumor Study HB99. Klin Padiatr. 215:159–165. 2003.(In German).
27	von Schweinitz D, Byrd DJ, Hecker H, et al: Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer. 33:1243–1249. 1997.
28	Roux PP and Blenis J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 68:320–344. 2004. View Article : Google Scholar : PubMed/NCBI
29	Warmann SW, Frank H, Heitmann H, et al: Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res. 144:43–48. 2008. View Article : Google Scholar : PubMed/NCBI
30	Ono K and Han J: The p38 signal transduction pathway: activation and function. Cell Signal. 12:1–13. 2000. View Article : Google Scholar
31	Chauhan D, Velankar M, Brahmandam M, et al: A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 26:2374–2380. 2007. View Article : Google Scholar : PubMed/NCBI
32	Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF and Fuchs J: The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer. 95:1795–1801. 2002. View Article : Google Scholar : PubMed/NCBI
33	Tse C, Shoemaker AR, Adickes J, et al: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI
34	Hwang JJ, Kuruvilla J, Mendelson D, et al: Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res. 16:4038–4045. 2010. View Article : Google Scholar : PubMed/NCBI
35	Paik PK, Rudin CM, Brown A, et al: A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol. 66:1079–1085. 2010. View Article : Google Scholar : PubMed/NCBI
36	Schimmer AD, O’Brien S, Kantarjian H, et al: A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res. 14:8295–8301. 2008. View Article : Google Scholar : PubMed/NCBI
37	Mason KD, Carpinelli MR, Fletcher JI, et al: Programmed anuclear cell death delimits platelet life span. Cell. 128:1173–1186. 2007. View Article : Google Scholar : PubMed/NCBI
38	Zhang H, Nimmer PM, Tahir SK, et al: Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 14:943–951. 2007.PubMed/NCBI